The patient was being treated with intravenous steroids (dexamethasone 15 mg/day) for 4 days, and oral prednisolone was prescribed for 5 days (20 mg/day). Ten days later, she visited the outpatient clinic for aggravated angioedema. Peripheral eosinophil count rose to 1,300/uL. The second high-dose steroid therapy was performed, and oral prednisolone was maintained at a dose of 20 mg/day. The prednisolone dose was tapered from 20 to 15 mg/ day for 1 month. However, her symptoms of angioedema relapsed and peripheral eosinophil count rose up to 620/uL.
Due to persistent angioedema, eosinophilia which was refractory to antihistamine and showed failure to taper the steroid, we started reslizumab 170 mg (3 mg/kg body weight) every 4 weeks. Persistent eosinophil activation status and angioedema despite the steroid therapy showed dramatic improvement (Figure B) . Biologics are recommended to be continued if the clinical response is achieved in severe asthma. 6 However, NEAE is known to be transient, we tried to stop reslizumab treatment as symptoms are relieved. After a reslizumab treatment period of 7 months and a follow-up period of 4 months, there were reductions in the daily maintenance dose of prednisolone (15 mg vs. 0 mg), the peripheral eosinophil count, and the serum levels of IL-5, EDN, and eosinophil cationic protein (Figure C and D) .
Recently, there has been a growing number of studies using eosinophil-targeted biologics (anti-IL-5 antibodies) in eosinophilic disorders including hypereosinophilic syndrome, eosinophilic granulomatosis and polyangiitis, eosinophilic esophagitis, and other disorders. 7 We report here a case of NEAE successfully and safely treated with reslizumab.
In conclusion, this is the first report to treat NEAE with reslizumab. Reslizumab is a treatment option in patients with NEAE.
